Applying whole-genome and whole-exome sequencing in breast cancer: a review of the landscape.
Hetvi GanatraJoecelyn Kirani TanAna SimmonsCarola Maria BigognoVatsala KhuranaAruni GhoseAdheesh GhoshIshika MahajanStergios BoussiosAkash ManiamOlubukola AyodelePublished in: Breast cancer (Tokyo, Japan) (2024)
Whole-genome sequencing (WGS) and whole-exome sequencing (WES) are crucial within the context of breast cancer (BC) research. They play a role in the detection of predisposed genes, risk stratification, and identification of rare single nucleotide polymorphisms (SNPs). These technologies aid in the discovery of associations between various syndromes and BC, understanding the tumour microenvironment (TME), and even identifying unknown mutations that could be useful in future for personalised treatments. Genetic analysis can find the associated risk of BC and can be used in early screening, diagnosis, specific treatment plans, and prevention in patients who are at high risk of tumour formation. This article focuses on the application of WES and WGS, and how uncovering novel candidate genes associated with BC can aid in treating and preventing BC.
Keyphrases
- end stage renal disease
- genome wide
- ejection fraction
- newly diagnosed
- chronic kidney disease
- stem cells
- small molecule
- prognostic factors
- peritoneal dialysis
- bioinformatics analysis
- high throughput
- current status
- gene expression
- dna methylation
- health insurance
- combination therapy
- transcription factor
- replacement therapy
- genome wide analysis